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Abstract
Background: Children with congenital hearing impairment benefit from early detection and
management of their hearing loss. These and related considerations led to the recommendation of
universal newborn hearing screening. In 2001 the first phase of a national Newborn Hearing
Screening Programme (NHSP) was implemented in England. Objective of this study was to assess
costs and effectiveness for hospital and community-based newborn hearing screening systems in
England based on data from this first phase with regard to the effects of alterations to parameter
values.
Methods: Design: Clinical effectiveness analysis using a Markov Model. Outcome measure: quality
weighted detected child months (QCM).
Results: Both hospital and community programmes yielded 794 QCM at the age of 6 months with
total costs of £3,690,000 per 100,000 screened children in hospital and £3,340,000 in community.
Simulated costs would be lower in hospital in 48% of the trials. Any statistically significant difference
between hospital and community in prevalence, test sensitivity, test specificity and costs would
result in significant differences in cost-effectiveness between hospital and community.
Conclusion: This modelling exercise informs decision makers by a quantitative projection of
available data and the explicit and transparent statements about assumptions and the degree of
uncertainty. Further evaluation of the cost-effectiveness should focus on the potential differences
in test parameters and prevalence in these two settings.
Background
Between one and two children per 1000 live births have a
moderate or greater bilateral permanent hearing loss
[1-3]. Children with congenital hearing impairment ben-
efit from early detection and management of their hearing
loss [4,5]. The neurological development of auditory
pathways requires acoustic stimulation in the first 18
months of life [6,7]. Communication deficits due to hear-
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ing impairment not discovered within the first two years
are not easily recovered by later rehabilitation. The conse-
quence may be delayed development of speech and lan-
guage as well as of other cognitive and social functions.
This delay is already measurable in the first 3 years of life
[8].
These and related considerations led to a comprehensive
review of the possible role of newborn hearing screening
in the UK [9]. The review recommended the introduction
of newborn hearing screening and in 2001 the first phase
of a national Newborn Hearing Screening Programme
(NHSP) was implemented in England; all areas of the
country are expected to be covered by 2005/6.
The first implementation phase of the Newborn Hearing
Screening Programme (NHSP) includes sites where the
screening is performed by Health Visitors at a home visit,
usually at 10 days of age. This model is called 'commu-
nity-based screening,' in contrast to the 'hospital based'
model where babies are screened in maternity hospital by
a new cadre of screeners prior to discharge with follow-up
of missed cases in a variety of ways.
The evaluation of the first phase of the NHSP, commis-
sioned by the Department of Health in accordance with
National Screening Committee (NSC) policy, included a
comparison of hospital-based and community-based
screening as a main comparison of interest. The measures
on which differences between the two models might a pri-
ori be expected are screen performance, maternal satisfac-
tion or anxiety, and costs. The NSC and others have been
clear that a national screen for newborn hearing is desira-
ble, with national quality assurance processes and ongo-
ing audit. The policy question is the extent to which a
national screen could encompass the two different mod-
els of delivery, and if it could, on what basis areas might
be permitted or encouraged to select one or the other
model. As the first step, the NHSP Steering Group wished
to verify that the data on screen performance, maternal
satisfaction/anxiety, and costs did not argue strongly
against the community-based model.
The aim of the modelling presented here was to determine
the costs and effectiveness for hospital and community-
based systems of Neonatal hearing screening in England
and Wales with a special regard to the effects of reasonable
alterations to parameter values.
Methods
We modelled the cost-effectiveness of the two screening
systems, hospital- and community-based screening using
some already-available costs data and screen performance
data from the first phase implementation, data from the
published literature on newborn hearing screening, and
further data collection on costs from the first phase of the
NHSP. We used a modified version of a decision-analytic
model which has been developed for a German Health
Technology Assessment funded by the German Federal
Ministry of Health [10].
We estimated absolute and incremental costs and effec-
tiveness of two newborn hearing screening settings. The
recommendations of the Panel on Cost-Effectiveness in
Health and Medicine were followed [11]. Target popula-
tion is all newborn infants. Health effects are presented in
form of number of quality weighed detected child months
(QCM), and true positive and false positive diagnoses at
certain developmentally important ages (6 and 12
months). If a hearing impairment was diagnosed within
the first month after birth, the baby added six QCM at the
age of six months. If the child's hearing loss was diag-
nosed (strictly, identified) at the age of five months, s/he
added only one detected child month at age six months.
QCM, true positives and false positives were reported at
the age of 6 and 12 months and with a time horizon of
120 months. Child months which were added until the
age of 6 months were multiplied with a weight of 1, child
months added after the age of 6 months were multiplied
with decreasing weighting. This was to ensure the interval
property of the outcome despite the fact that the incre-
mental benefit of detecting a hearing problem decreases
with time.
The model
A state-transition (Markov) model [12] was developed to
characterise the process of screening and diagnosis
through all possible stages (see Figure 1). A child can be in
one of the following states:
- Unknown status
- Healthy (hearing) confirmed by diagnostic test or screen-
ing – true negative
- Healthy (hearing) not confirmed by diagnostic test
- Hearing impaired confirmed by diagnostic test or screen-
ing – true positive
- Thought to be healthy (hearing) but hearing impaired –
false negative
- Thought to be hearing impaired but healthy (hearing) –
false positive
- Not followed up/not compliant
The model starts with a cohort of newborns being of
unknown status and applies transition probabilities recur-BMC Health Services Research 2006, 6:14 http://www.biomedcentral.com/1472-6963/6/14
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sively to simulate how children progress through different
states. In each cycle (lasting one month) children can
undergo several possible transitions which accrue costs
and utility weights. Ultimately all children from the initial
cohort are diagnosed as healthy or as impaired or, if they
are healthy, some remain 'undiagnosed' (but with true
state healthy).
Data and assumptions
A predefined and externally reviewed literature search on
newborn hearing screening on all relevant electronic data-
bases has been performed. Search strategy and methods
have been reported in detail elsewhere [13]. Detected
publications were scored according to a standardised
questionnaire and included or not. All assumptions made
and parameters used are shown in Table 1.
Prevalence of congenital hearing disorders was derived
from comprehensive literature searches. The probability
of hearing children presenting with falsely suspected hear-
ing disorder was estimated by a panel of experts. The
probability of being detected at a certain age without
screening was estimated from a survey of activity in an
area of Germany in 1998 and 1999 [14]. Positive predic-
tive values were calculated from the empirical yield data.
In order to account for the heterogeneity of study sites,
positive predictive values were pooled using a random
effects model [15]. Test parameters have then been calcu-
lated using Bayes' theorem.
The slope of the weighting function was estimated by
experts making the following assumptions: each month
detected before the age of 6 months is weighted with 1, on
the general assumption that children detected (and
treated) within the first 6 months of life can develop typ-
ical speech and language abilities. If not detected within
the first 12 months, profoundly and severely impaired
children will end up with a weight of 0.85, and moder-
ately impaired children with a weight of 0.90. Presuming
that 50% of the children with permanent congenital hear-
ing disorders are moderately impaired gives a weight of
0.875 for every month which is detected after the first
birthday. The weights between 6 and 12 months were cal-
culated by linear extrapolation.
Model assumptions
Screening and diagnostic procedures are presented under
the assumption of conditional independence, i.e. test
parameters are independent of the prevalence of the con-
dition and test results of diagnostic testing are independ-
ent of test results of screening procedures. This is plausible
because screening and diagnostic testing are based on dif-
ferent testing principles.
Screen performance data and costs
Screen performance data and costs for screening and diag-
nosis have been derived from empirical data from the
NHSP first wave sites.
All community-based areas – East Sussex, Shropshire,
Wiltshire (Bath) and Wiltshire (Swindon) – and all hospi-
tal-based areas that had started NHSP before 1st May 2002
– Avon, Barnsley, Bradford, Buckinghamshire, Dewsbury,
Manchester, North Staffordshire, Northumberland, and
Oxford – were included in the study. Four community-
based areas and seven hospital-based areas were able to
provide data. Table 2 gives the annual birth rates of the
included areas.
The following data have been provided by the 11 sites and
included into the cost/effectiveness calculation: Screen
performance data (number of screened, number of refer-
rals, number of true cases), staff grade and full-time equiv-
alent (screeners, local coordinator, team leader, clerical
staff), quantity, make and model of screening equipment,
quantity, make and model of computers and printers,
quantity and make of consumables, travel costs (exclusive
travel associated with training) and any additional costs
(e.g. recruitment, refurbishing rooms, stationary). Addi-
tional information was obtained from National Health
Service salary scales, the National Health Service Rehabil-
itation Services Catalogue (screening equipment and con-
sumables), the Medical Research Council Institute of
Hearing Research for calibration costs, IT costs and train-
ing costs. Additionally, training costs during screening
Model figure Figure 1
Model figure.
Unknown
status
Not 
screened/not 
compliant
True positive 
(confirmed by
test)
Hearing (not 
confirmed by
test)
True negative 
(confirmed by
test)
False positive
False
negativeBMC Health Services Research 2006, 6:14 http://www.biomedcentral.com/1472-6963/6/14
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and IT training have been obtained. Audiology services
reported costs for 10 consecutive referrals and all true
cases for audiology follow-up costs.
Screen performance data
Incidence and prevalence of congenital permanent bilat-
eral hearing loss were assumed equal.
Staff costs
To calculate salaries, midpoint was taken.
Within the community model, health visitors' time for
NHSP was estimated at 1%. This estimate was based on a
Health Visitor screening on average 1.3 children per week
and spending ca 20 minutes on the screen, which is based
on data from the sites and Netten et al [16].
National insurance and superannuation was taken as
13%.
Non-staff related costs refer to the overheads, building
capital and equipment costs associated with running
audiology services. Most NHSP services use a number of
different facilities to deliver the different components of
the programme and do not have these figures readily
available. Hence, to determine these costs, the following
steps have been taken: Allowances for indirect overheads
(the costs of the support services such as human resources,
finance and estates required to carry out the services main
functions) have been taken as fixed cost of £2216, and
building capital (the costs assigned to treatment and non-
treatment space) relative to the level of pay scale based on
Netten et al [16].
Direct overheads i.e. the costs associated with lighting,
heating and cleaning were assumed to be 11% of the sum
of staff costs, indirect overheads and building capital. This
was based on previous studies carried out in hospital set-
tings where the direct overheads were found to account
for 4% to 18% (midpoint 11%) of total costs [17,18]. As
there are no data available, this was equally assumed for
community settings. Costs associated with staff turnover
have not been included. Staff costs for 10 years were cal-
culated based on the first year costs, except for the Team
Leader's post which is included for the first 2 years only
and has not been included for the following 8 years.
Equipment and IT costs
When equipment is totalled over 10 years, a 5% annuity
for each year of life has been allowed for. VAT at 17.5%
has been included.
Consumable costs
The sites provided information of the quantity of consum-
ables they used in November 2002 and prices obtained
from NHS Purchasing and Supply Agency. The figure was
multiplied by 12 for the whole year cost. VAT at 17.5% has
been included.
Table 1: Data input for the model
Estimated parameter Setting Baseline estimate Range for sensitivity 
analysis
Extremes Source
Prevalence of newborn hearing impairment % H
C
0.15 0.09–0.3 0.01–0.2
0.01–0.2
Literature
[3][4][14][15][16]
Sensitivity of screening % H
C
96 96–100 70–99
70–99
Literature
[10]
Specificity of screening % H
C
99 99 70–99 data from sites, calculated
Coverage of screening % H
C
97 97 50–99 data from sites
Follow-up after screening % H
C
95 95 Authors' estimate
Healthy children under suspicion of hearing 
impairment %
H
C
0.1 0.1 Authors' estimate
Discounting factor Costs % H
C
6 per year
6 per year
Effects % H
C
1.5 per year
1.5 per year
Probability of "natural" discovery without 
systematic screening
H
C
Distribution, smoothed
Weibull curve
Median age at 
diagnosis 18 months
Empirical data
[18]
Costs of screening per child H
C
£ 35.58
(32–40)
£ 31.99
(29–35)
£ 28–59
£ 27–43
Data from sites
Costs of audiological follow-up of referrals H
C
£ 160 £ 160 Estimate from sites
H = hospital C = communityBMC Health Services Research 2006, 6:14 http://www.biomedcentral.com/1472-6963/6/14
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Calibration costs
Calibration costs were based on the manufacturers' speci-
fications.
Travel costs
Only staff travel costs directly associated with the screen
were included. Data was obtained from the proformas
filled in by the Team Leaders.
Training costs
Initial training cost calculation was based on cost of attend-
ing, cost of conducting the training, venue costs. Cost of
attending and conducting the training consist of travel
and accommodation costs and cost of time spent by par-
ticipants and deliverers. Cost of time spent was calculated
as number of days attending/delivering training divided
by number of workdays per year multiplied by annual sal-
ary. Data was obtained from the proformas filled in after
each training event. Refresher training cost calculation was
based on an assumption that refresher training would be
0.5 day a year per screener.
Costs of audiological follow-up of screen referrals (false positives)
We assumed the typical audiological assessment which
confirms false positive status consisted of an ABR (Auto-
mated Evoked Brainstem Response). We assumed a cost
of £160 per referral.
Societal costs
Costs to the families associated with NHSP screening
(travel costs, time off from work, childminding costs)
were not included.
Costs and their standard deviations were calculated sepa-
rately for both settings and weighted with the number of
children screened per site.
Discounting
Future costs were discounted at a rate of 6% per year,
future effects at a rate of 1.5% per year. Yearly discount
rates have been converted to monthly discount rates.
Sensitivity analysis
One-way and multiple sensitivity analyses were per-
formed on all relevant parameters.
Multivariate simulations were used for probabilistic mod-
elling (Monte Carlo). The simulation associates with each
of the model variables a probability density function
which represents our uncertainty about a fixed but
unknown value. The ranges for test parameter estimates
derived empirically and from the literature assumed beta
distribution based on available ranges of estimates, and
ranges for empirical cost data assumed gamma distribu-
tion. The model was evaluated for 1,000 trials.
As the number of sites was small the parameter estimates
were estimated in a context of uncertainty. We wanted to
evaluate the impact of extreme parameter changes on out-
come and decision between alternative settings. As
described by Felli and Hazen [19], Monte Carlo simula-
tion was performed on one parameter at a time allowing
for the input of extreme values, keeping the other param-
eters fixed at their baseline level. This analysis was done
for prevalence, sensitivity, specificity, coverage and costs.
The aim was to show if there is any variation in the input
parameter that might result in a change of preference
between sites in comparison to the baseline result. One
setting can be defined as more cost effective than another
if it is (a) less costly and at least as effective, (b) more
effective and no more costly, (c) more costly and more
effective and its additional costs per unit of effectiveness
are considered worth paying, (d) less costly and less effec-
tive and the additional costs per extra unit of effectiveness
for the alternative setting are not considered worth pay-
ing. One unit of effectiveness is defined as one quality
weighted detected child month (QCM). The specific goals
of the extremes analysis are
- to show the probability that one setting (eg. hospital) is
more cost-effective than the other under the assumption
that the two sites differ in one parameter, and
Table 2: Annual birth rates of participating areas
Area Birth rate per 1,000 inhabitants
Avon 11.7
Barnsley 11.7
Bradford 14.5
Bucks 12.7
Calderdale & Huddersfield 13.1
Camden & Islington 14.1
Dewsbury 13.1
East London & City 17.8
East Sussex 12.6
Manchester 13.5
North Cheshire 12.3
North Derbyshire 10.8
North Staffordshire 11.0
Northumberland 11.6
Nottingham 11.5
Redbridge & Waltham Forest 14.8
Oxford 12.6
Sheffield 11.4
Shropshire 11.8
Southampton 11.2
Stockport 11.2
Wiltshire (Bath) 10.6
Wiltshire (Swindon) 12.6BMC Health Services Research 2006, 6:14 http://www.biomedcentral.com/1472-6963/6/14
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- to indicate which difference in a certain parameter
between sites might result in substantial differences in
costs.
This was achieved by the following procedure: The simu-
lation was run twice with all parameters except one held
fixed, the first time with the extreme high estimate of the
parameter, the second time with the extreme low estimate
of the parameter. This resulted in "high" and "low" esti-
mates for costs and QCM for each setting. Differences of
costs and QCM were then calculated using the "high" esti-
mate for hospital and the "low" estimate for community
and vice versa. This was done for each of the parameters
mentioned. If QCM between hospital and community did
not vary, only cost differences were calculated. If both
costs and QCM varied the resulting distributions in mean
differences of costs and QCM were combined using the
Net Benefit Approach [20]. The Incremental Cost Effec-
tiveness Ratio (ICER) is defined as the additional average
cost of producing one more unit of effectiveness, here the
additional cost for one more QCM achieved in one of the
settings, eg. in hospital. Health care planners might decide
on a ceiling value λ for these additional costs so that one
setting should replace another setting only if the ICER is
below this λ. From the distributions of cost and effective-
ness differences the probability that one setting is cost-
effective compared to another is calculated depending on
a range of values for the ceiling ratio λ and presented in
the form of a cost-effectiveness acceptability curve
[21,22]. The probabilities presented in this curve can be
used for formal statistical inference.
Data 3.5 (TreeAge Inc.) was used to construct and run the
Markov model and Excel (Microsoft Corp.) was used to
validate the model and to perform the Monte Carlo simu-
lations.
Results
We modelled costs and effectiveness of universal newborn
hearing screening in two different settings. As test param-
eters were held to be constant across hospital and commu-
nity sites there was no difference in effectiveness, only in
costs. Both hospital and community settings yielded 134
true positive cases (89% of all cases) and 794 quality
weighed detected child months (QCM) at the age of 6
months with total costs of £3,690,000 per 100,000
screened children in hospital and £3,340,000 in commu-
nity. Table 2 shows the annual birth rates of the participat-
ing areas. Table 3 and Table 4 show the results of base case
and one way sensitivity analysis. Costs per QCM were
higher by £25 in hospital-based sites. Sensitivity analysis
showed that prevalence had the most important influence
on costs per weighted detected child month. Lower preva-
lence would result in substantial higher costs for each site
and in higher incremental costs. The model was, however,
rather insensitive to large variations of the other test
parameters. Since incremental effectiveness was set zero
for base case and sensitivity analysis, the ICER (incremen-
tal cost effectiveness ratio) was not available. Figure 2
shows the results of the Monte Carlo simulation. Costs
would be lower in hospital sites in 48% of the trials.
Results of extremes analysis
Higher prevalence in hospital resulted in higher costs (fig-
ure 3) and higher amount of QCM. Figure 4 shows the
cost-effectiveness acceptability curve for the assumption
that prevalence in hospital was higher than in community
sites (0.002 in H versus 0.001 in C). If decision makers
were willing to pay at least £ 500 per QCM gained, the
probability of hospital being more cost-effective under
this assumption would be 95%. If the willingness to pay
was below £ 30 per QCM, community sites were more
cost-effective with a probability of 95%. For the assump-
Table 3: Model results base case assumption (discounted) for a hypothetical cohort of 100,000 children
outcome Alternative settings hospital community incremental
Base case Base case
effects
QCM at 6 months 794 794
QCM at 12 months 1536 1536
QCM at 120 months 13751 13751
TP at 6 months 134 134
TP at 120 months 150 150
FP after screening and additional diagnostic 12 12
costs
Costs per 100,000 at 120 months £ 3.690.022 £ 3.343.572 £ 346.450
Cost per detected child £ 25.813 £ 23.390 £ 2423
Cost per QCM £ 268 £ 243 £ 25
QCM = quality weighed detected child months
TP = true positives
FP = false positivesBMC Health Services Research 2006, 6:14 http://www.biomedcentral.com/1472-6963/6/14
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tion that prevalence in community sites was higher than
in hospital sites, community sites were more cost-effective
for any ceiling ratio. Any difference in sensitivity predicted
differences in costs. Higher sensitivity in any site resulted
in higher costs. If decision makers were willing to pay at
least £ 300 per QCM gained, the probability of hospital
being more cost-effective under the assumption of higher
sensitivity in hospital would be 95%. If willingness to pay
were below £ 150 per QCM, community sites would be
more cost-effective with a probability of 95%. For the
assumption that screen sensitivity in community sites was
higher than in hospital sites, community sites were more
cost-effective for any ceiling ratio. Low coverage resulted
in low costs. With coverage in hospital being higher than
in community, community settings would be more cost-
effective with a probability of 95% if willingness to pay
were below £ 350 per QCM. With coverage in hospital
being lower, hospital settings would be more cost-effec-
tive with a probability of 95% if willingness to pay were
below £ 200. Differences in screen specificity between
hospital and community sites resulted in cost differences
but not in effectiveness differences. Higher specificity
resulted in lower costs. Any differences in costs per screen-
ing procedure resulted in output cost differences. With all
other parameters held constant in both settings, variance
in input costs completely predicted variance in output
costs.
Discussion
We applied a decision-analytic Markov model to empiric
data of first stage implementation areas of NHSP in Eng-
land to evaluate cost and effectiveness of different settings
Incremental costs between hospital and community sites,  Monte Carlo simulation with 1000 trials Figure 3
Incremental costs between hospital and community 
sites, Monte Carlo simulation with 1000 trials. Nega-
tive incremental costs indicate higher costs in community 
sites. The solid dot shows the base case result.
Table 4: One-way sensitivity analyses
Item Hospital site Cost per QCM Community site Cost per QCM Incremental
Base case £ 268 £ 243 25
Prevalence (%)
low (0.09) £ 437 £ 395 42
high (0.3) £ 142 £ 129 13
Sensitivity (%)
low (0.96) £ 268 £ 243 25
high (100) £ 263 £ 239 24
Costs (£)
low (H 32, C 29) £ 243 £ 222 21
high (H 40, C 35) £ 299 £ 264 35
QCM = quality weighed detected child month, detected child months weighted by a utility value indicating the prognosis of further speech 
development
H = Hospital
C = Community
Costs and effectiveness of screening in hospital and commu- nity sites Figure 2
Costs and effectiveness of screening in hospital and 
community sites. Results of probabilistic Monte Carlo sim-
ulation (1000 trials).BMC Health Services Research 2006, 6:14 http://www.biomedcentral.com/1472-6963/6/14
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for newborn hearing screening. Base case assumptions
with constant test parameters but cost difference between
hospital and community settings yielded a cost difference
of £25 per quality weighted detected child month (QCM):
To detect one hearing impaired child one month earlier
produced costs of £268 in hospital settings and of £243 in
community settings. This cost difference, however, was
not statistically significant. Probabilistic multivariate
Monte Carlo simulation revealed that in nearly half of
1000 simulated trials community settings would yield
higher costs than hospital settings. The cost-effectiveness
of the two newborn screening models – hospital-based
and community-based – did not differ significantly,
assuming comparable screen performance for the two
newborn screening models. Projected magnitude of costs
per detected child was comparable to the costs found by
other UNHS models [23], proving the model to give
results of external validity. As this is the first model to
report costs per quality weighted child month, these
results can not be directly compared to other findings.
Up to now preliminary data were too sparse to detect any
differences of important input parameters – like screen
performance and program costs – between settings.
Extremes analyses showed that any statistically significant
difference in prevalence, sensitivity, specificity and costs
would result in significant differences in cost-effectiveness
between settings. Any further evaluation of cost-effective-
ness between different programme alternatives should
evaluate in the first place if there is substantial difference
in terms of these parameters.
Our study has several limitations. Even though QCM was
weighted, it is a surrogate parameter for the actual burden
of disease for the child. To date, however, there is no study
yielding empirical data on a more general effectiveness
measure such as quality adjusted life years. There are
drawbacks of this study concerning uncertainty on model
parameters. There is still only limited evidence for further
benefits of early diagnosis and intervention. Weighting
assumptions in the presented model are therefore only
estimates of the potential impact of late diagnosis and the
actual child's burden of disease. To date there is no further
studies should be conducted on this issue. Other parame-
ter uncertainties should be ruled out as soon as long term
data from the NHSP implementation are available.
Probabilistic analysis of the incremental cost-effectiveness
ratio can be used to give ceiling values. Policy makers can
then decide on a fixed incremental effectiveness they
would like to obtain by introducing a screening program
and the model will show how probable this outcome will
be under the assumption of parameter uncertainty.
As a part of ongoing and future research the NHSP Evalu-
ation aims to identify factors predicting high cost-effec-
tiveness for either model and to compare maternal
satisfaction/anxiety in hospital-based and community-
based setting.
Conclusion
The value of this modelling exercise lies in the provision
of information to decision makers by a quantitative pro-
jection of available data and the explicit and transparent
statements about assumptions and the degree of uncer-
tainty. This has been achieved at an early stage of imple-
mentation. The evaluation of the NHS Newborn Hearing
Screening Programme will serve as a valuable tool and
example to justify and improve large scale screening pro-
grammes.
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Cost-effectiveness acceptability curve Figure 4
Cost-effectiveness acceptability curve. This shows the 
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another for a given ceiling value and for the assumption that 
prevalence in hospital sites is higher than in community sites. 
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